The EE-ASI project is an innovative ASI approach which combines technologies brought by academic partnerships and two SMES.

A T cell epitope which targets the beta cell will be combined with tolerogenic IL-10 cytokine which will target cells presenting the antigen through gold nanoparticles and will be delivered into very superficial layers of the skin using microbore needles. Validation of manufacture and in vitro and in vivo efficacy will firstly be demonstrated and will then followed by a phase 1 clinical study in order to confirm its safety in human beings.

http://www.ee-asi.eu/

  • EE-ASI

    The EE-ASI project is an innovative ASI approach which combines technologies brought by academic partnerships and two SMES.

    A T cell epitope which targets the beta cell will be combined with tolerogenic IL-10 cytokine which will target cells presenting the antigen through gold nanoparticles and will be delivered into very superficial layers of the skin using microbore needles. Validation of manufacture and in vitro and in vivo efficacy will firstly be demonstrated and will then followed by a phase 1 clinical study in order to confirm its safety in human beings.

    http://www.ee-asi.eu/

  • EBOVAC 2

    The EBOVAC2 project is intended to assess the safety and efficacy of a new preventative vaccine regimen against EVD.

    EBOVAC2 will provide solid data on the safety and immunogenicity of the regimen and the immune response to vaccines will be compared at different administration intervals. To do this, phase 2 studies have been conducted in Burkina Faso, the Ivory Coast, France, Rwanda, Uganda and the United Kingdom.

    http://www.ebovac2.com/

  • EBOLAMODRAD

    The overall objective of this project is to develop and provide rapid, ambulatory diagnostic tools which will considerably increase our ability to manage the current situation with Ebola virus in West Africa and best prepare us for future epidemics.

    EbolaMoDRAD is also setting up a programme to increase capacity in West Africa and practical training in non-endemic countries (neighbouring countries to endemic areas) in the fields of managing epidemics, diagnosis and the application of tools/results from EbolaMoDRAD.

    http://www.ebolamodrad.eu/

  • CARMMA

    CARMMA is based on the new hypothesis that the comorbidities of obesity are related premature senescence of adipose tissue (AT).

    The primary objective of CARMMA is to define the mechanisms through which AT senescence contributes to the initiation and progression of the target comorbidities in the project, which are metabolic cardiomyopathy and sarcopenia.

  • AGEDBRAINSYSBIO

    A European group of university laboratories and scientists working for industrial SME companies, combining integrated systems biology and comparative genomics in order to study ageing of the human brain and/or the most common age-related diseases.

    Particular attention is paid to Alzheimer’s disease with the aim of identifying and validating new molecular targets and new biomarkers.

    http://agedbrainsysbio.eu/

  • EHVA

    The aim of EHVA is to develop several innovative concepts in vaccines against HIV, both for prophylaxis and treatment.

    The prophylactic vaccine strategy is based on a the development of new candidate vaccines and a vaccination system which is able to improve protective antibody responses, whereas the approach to a therapeutic vaccine will examine the measures which contribute to developing a functional cure, combining vaccines with other immunological interventions.

    http://www.ehv-a.eu/

  • ENSAT-HT

    This project will help to construct and assess a stratified health promotion programme based on so-called “omics” technologies for patients suffering from an endocrine form of hypertension.

    We will define the specific “omic” profiles for patients suffering from primary hyperaldosteronism, pheochromocytoma/functional paraganglioma and Cushing syndrome by combining high output genetic, genomic and metabolometric data, the effects being annotated with bioinformatics modelling. The profiling based on so-called “omics” technologies should help in the early identification of patients with preclinical phenotypes and hypertensive patients who are grouped into endocrine groups and who may benefit from personalised treatment.

    http://www.ensat-ht.eu/

  • ERINHA

     

    ERINHA is a research infrastructure intended to improve European preparation and response, in terms of research, to combat highly infectious emergent and re-emergent diseases.

    The aim of the preparatory phase of ERINHA is to reach the necessary maturity to successfully set up the infrastructure and ensure that the operational phase begins.

    http://www.erinha.eu/

WordPress Lightbox